Effects Of Alprostadil On Liver Failure Of Viral Hepatitis:A Meta-Analysis Of RCT

Objective:To evaluate the effect of alprostadil on treating liver failure of viral hepatitis.Methods:We search the related literatures from Pubmed, Cochrane Library、Embase、China National Knowledge Infrastructure, Wanfang database, VIP database and Chinese biomedical abstract database before Jan,2016. The terms in English and Chinese including Alprostadil, PGE1, Prostaglandin e, Liver failure, Hepatic failure and Viral hepatitis. Screen out the randomized control trails (RCTs) according to the inclusion and exclusion criterias. then using the Jadad score to assess the quality of literatures of randomized clinical trials. We use the software STATA to Meta analysis, Odds ratio (OR) as the effect size to evaluate the effect of alprostadil on treating liver failure of viral hepatitis.Results:A total of 28 studies were included. Which were proved to have almost no heterogeneity. The pooled OR for effect of treatment was 2.87,95%CI (2.42-3.40). The pooled OR for incidence of hepatic encephalopathy (HE) and hepatorenal syndrome (HRS) were 0.64,95%CI(0.42-0.98) and 0.30, 95%CI (0.19-0.46), and there were significant differences(P<0.01).Conclusion:1、Compared with the control group, the alprostadil experiment group has higher total efficienty.2、The alprostadil experiment group has lower incidence of hepatic encephalopathy and hepatorenal syndrome.3、Aalprostadil presents better drug safety and less side effect.